Based on the same rationale that inhibiting PKM2 might represent an effective chemotherapeutic approach for certain cancers, some studies have reported success with the orally available small molecule pan-PDK inhibitor dichloroacetate (DCA), which increases PDC activity and reduces the pool of pent up Warburg intermediates [22,23,84,85]. The gene discussed is PDC; the disease is cancer.